CapsoVision (NASDAQ:CV) Stock Price Down 2.2% - Should You Sell?

Key Points

• CapsoVision's stock price fell 2.2% during mid-day trading on Tuesday, closing at $3.56, after trading as low as $3.52.
• The company reported a significant earnings miss, with an EPS of ($2.02), failing to meet analysts' expectations of ($0.11), although revenue was slightly above estimates at $3.32 million.
• Analysts have mixed opinions on the stock; Benchmark initiated coverage with a "speculative buy" rating and $5.00 price target, while Roth Capital set a "buy" rating with a target of $6.00.

Shares of CapsoVision, Inc. (NASDAQ:CV - Get Free Report) fell 2.2% on Tuesday . The stock traded as low as $3.52 and last traded at $3.56. 19,676 shares changed hands during trading, a decline of 24% from the average session volume of 26,005 shares. The stock had previously closed at $3.64.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CV. Wall Street Zen raised shares of CapsoVision to a "hold" rating in a research report on Sunday, July 13th. Benchmark started coverage on shares of CapsoVision in a report on Monday, July 28th. They issued a "speculative buy" rating and a $5.00 price objective on the stock. Finally, Roth Capital set a $6.00 price objective on shares of CapsoVision and gave the company a "buy" rating in a report on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Strong Buy" and an average price target of $5.50.

CapsoVision Price Performance

The company has a 50-day moving average price of $4.05.

CapsoVision (NASDAQ:CV - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($2.02) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($1.91). The firm had revenue of $3.32 million during the quarter, compared to analyst estimates of $3.20 million.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.